An Oral Peptide for Ulcerative Colitis: Icotrokinra’s Phase 2 Signal, Without the Shortcut Claims

A once-daily pill produced a week-12 clinical response in 55% to 63% of adults with moderately to severely active ulcerative colitis, compared with 27% on placebo. The drug is icotrokinra, an oral peptide that blocks the interleukin-23 receptor. The result is notable not because it proves a cure, but because a peptide designed to interrupt an immune signal usually targeted with injections or infusions showed activity as a pill in a randomized human trial.

That distinction matters. Ulcerative colitis is a chronic inflammatory disease, and a response is not the same as remission. The trial was phase 2b, lasted 12 weeks for its primary endpoint, and was funded by the manufacturer. Here is what the published data do—and do not—say.

The study: 252 people, four groups

In the ANTHEM-UC phase 2b trial, 252 adults with moderately to severely active ulcerative colitis were randomly assigned to once-daily icotrokinra at 400 mg, 200 mg, or 100 mg, or to placebo. The study was double-blind. Its primary endpoint was clinical response at week 12. Clinical remission, symptomatic remission and endoscopic improvement were secondary outcomes.

The response rates at week 12 were 63% with 400 mg, 58% with 200 mg and 55% with 100 mg. In the placebo group, 27% met the response endpoint. Each dose comparison with placebo was statistically significant (P<0.001).

The absolute differences versus placebo were 36 percentage points for 400 mg, 31 points for 200 mg and 28 points for 100 mg. Put plainly, in this trial more participants receiving icotrokinra met the defined response criteria by week 12 than participants receiving placebo. Those differences are encouraging, but they should not be translated into a promise that an individual patient has a particular chance of benefit. Trial eligibility, baseline disease, endpoint definitions and the study setting all matter.

Response is not remission

The most important word in the headline is response. It is not interchangeable with remission, and it does not mean that inflammation disappeared or that the disease was cured.

At week 12, clinical remission occurred in 30% of the 400-mg group and 11% of the placebo group (P=0.006). The 200-mg group had a 24% remission rate; its comparison with placebo had P=0.054. Because the study used a fixed-sequence testing procedure to control for multiple comparisons, formal testing of additional secondary outcomes stopped after that comparison did not meet the prespecified threshold. That statistical rule matters: the 100-mg remission result and later endpoints should not be presented as if each had an independently confirmed statistical win.

Symptomatic remission was reported in 46% of the 400-mg group versus 19% with placebo. Endoscopic improvement was reported in 37% versus 14%, respectively. These outcomes add useful context, but they are not proof of long-term disease control. The study’s primary result remains a 12-week clinical response.

This is the difference between a promising signal and a treatment decision. A phase 2 trial helps determine whether a drug merits larger studies. It cannot establish how well it works across the wider population, how durable the benefit is, or how it compares with established therapies.

Why an oral peptide is scientifically interesting

Icotrokinra blocks the interleukin-23 receptor (IL-23R), interrupting a signaling pathway involved in inflammatory immune activity. The molecule is a peptide, but it is engineered for oral delivery. That combination is unusual: many peptide medicines are broken down in the digestive tract and therefore require non-oral delivery. The study is a clinical demonstration that this particular engineered drug can be administered orally; it does not mean ordinary peptides, supplements or research vials can be swallowed and expected to work.

The treatment also differs from simply taking an oral steroid or another broadly acting anti-inflammatory medicine. Its intended target is a defined immune pathway. Still, the trial does not prove that the mechanism will make treatment safer, more convenient in every respect, or better than biologic injections. Oral dosing can be appealing, but efficacy, safety, access, cost and the practical burden of daily use all count.

Icotrokinra has also been studied in psoriasis, another immune-mediated condition involving IL-23 biology. That background makes the new ulcerative-colitis result part of a broader clinical-development program, not an isolated biological theory. But success in one disease cannot be assumed to transfer to another. The current trial must stand on its own data.

Safety: similar overall adverse-event rates through week 28

Through week 28, at least one adverse event was reported in 60% of participants in the 400-mg group, 66% in the 200-mg group, 66% in the 100-mg group and 62% in the placebo group. Serious adverse events were reported in 2%, 5%, 0% and 10%, respectively.

Those figures are reassuring as an early comparison, but they do not establish that the drug is safe for long-term use. A trial with 252 participants cannot reliably detect every uncommon or delayed risk. Nor should the lower serious-event percentage in a treatment arm be read as evidence that the drug prevents serious events; the groups are small, and the study was not designed to prove that claim.

The published abstract gives these overall rates but does not provide enough detail to characterize every adverse event or subgroup. Readers should consult the full paper and its supplementary materials for the complete safety tables and methods. Longer follow-up and larger studies are needed to clarify durability and uncommon harms.

What the trial cannot tell us yet

First, 12-week response is an early checkpoint, not a forecast of years of control. The paper reports adverse-event rates through week 28, but that does not turn the primary efficacy endpoint into a long-term remission result.

Second, placebo is not an active comparator. The study does not show that icotrokinra is more effective than an approved biologic, small-molecule medicine or other standard treatment. It also does not tell clinicians how to sequence it after treatment failure.

Third, the trial was funded by Johnson & Johnson, and several authors were company employees. Industry funding does not invalidate randomized results, but it is relevant context. Independent replication, transparent data and the full protocol and supplement are part of judging how much confidence to place in the findings.

Finally, this is not a prescription or dosing guide. The doses in a clinical trial are study regimens, not directions for self-treatment. Icotrokinra remains an investigational treatment for ulcerative colitis based on this phase 2b evidence; readers should not assume that availability, approval or suitability has been established.

The Oria take

The genuinely new piece is not simply “a peptide pill works.” It is that a specifically engineered oral IL-23 receptor-blocking peptide produced a clear week-12 response signal across three tested doses in a blinded, placebo-controlled phase 2b ulcerative-colitis trial. The 400-mg arm also showed higher reported rates of remission, symptom remission and endoscopic improvement than placebo, while the trial’s testing hierarchy limits how confidently some secondary comparisons can be interpreted.

The next questions are practical and consequential: can larger trials reproduce the benefit, does remission persist, how does the drug compare with existing options, and what does longer-term safety look like? Until those answers arrive, icotrokinra is an important investigational result—not an established alternative to current care.

Evidence grade: B — A randomized, double-blind, placebo-controlled phase 2b trial in humans showed a statistically significant week-12 clinical-response advantage at all three tested doses. Confidence is limited by the modest sample, short primary efficacy window, sponsor funding, absence of an active comparator and the need for confirmatory later-phase evidence.

This article is for educational purposes only and is not medical advice. Ulcerative colitis can require urgent assessment and ongoing specialist care. Do not start, stop or change prescribed treatment based on this article; discuss treatment decisions with a qualified clinician. Oria provides research-focused information and connects users with clinician-led teleconsultation; it does not replace diagnosis or medical care.

Sources

- Abreu MT, et al. “Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis.” New England Journal of Medicine. Published online October 14, 2026; 395:1495–1504. doi:10.1056/NEJMoa2604435 — https://www.nejm.org/doi/full/10.1056/NEJMoa2604435

- PubMed record and abstract: PMID 42874103 — https://pubmed.ncbi.nlm.nih.gov/42874103/

- ANTHEM-UC clinical trial registration: ClinicalTrials.gov NCT06049017 — https://clinicaltrials.gov/study/NCT06049017

- Johnson & Johnson, sponsor report on week-28 findings: Icotrokinra in ulcerative colitis — https://www.jnj.com/media-center/press-releases/icotrokinra-maintains-standout-combination-of-therapeutic-benefit-and-a-favorable-safety-profile-in-once-daily-pill-through-28-weeks-in-ulcerative-colitis (company source; not independent confirmation)